ID   SYK_HUMAN               Reviewed;         597 AA.
AC   Q15046; A8MSK1; D3DUK4; O14946; Q96J25; Q9HB23;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 3.
DT   10-MAY-2017, entry version 165.
DE   RecName: Full=Lysine--tRNA ligase;
DE            EC=6.1.1.6;
DE   AltName: Full=Lysyl-tRNA synthetase;
DE            Short=LysRS;
GN   Name=KARS; Synonyms=KIAA0070;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CYTOPLASMIC).
RC   TISSUE=Brain;
RX   PubMed=9278442; DOI=10.1074/jbc.272.36.22809;
RA   Shiba K., Stello T., Motegi H., Noda T., Musier-Forsyth K.,
RA   Schimmel P.;
RT   "Human lysyl-tRNA synthetase accepts nucleotide 73 variants and
RT   rescues Escherichia coli double-defective mutant.";
RL   J. Biol. Chem. 272:22809-22816(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MITOCHONDRIAL), SUBCELLULAR
RP   LOCATION, AND VARIANT SER-595.
RX   PubMed=10952987; DOI=10.1074/jbc.M006265200;
RA   Tolkunova E., Park H., Xia J., King M.P., Davidson E.;
RT   "The human lysyl-tRNA synthetase gene encodes both the cytoplasmic and
RT   mitochondrial enzymes by means of an unusual alternative splicing of
RT   the primary transcript.";
RL   J. Biol. Chem. 275:35063-35069(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CYTOPLASMIC), AND
RP   VARIANT SER-595.
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S.,
RA   Seki N., Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II.
RT   The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CYTOPLASMIC).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-10; 112-127; 142-148; 231-241; 306-314 AND
RP   486-492, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY (ISOFORM CYTOPLASMIC).
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Kolch W.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [8]
RP   FUNCTION.
RX   PubMed=5338216; DOI=10.1016/0006-291X(66)90415-3;
RA   Zamecnik P.C., Stephenson M.L., Janeway C.M., Randerath K.;
RT   "Enzymatic synthesis of diadenosine tetraphosphate and diadenosine
RT   triphosphate with a purified lysyl-tRNA synthetase.";
RL   Biochem. Biophys. Res. Commun. 24:91-97(1966).
RN   [9]
RP   INTERACTION WITH AIMP2.
RX   PubMed=9878398; DOI=10.1006/jmbi.1998.2316;
RA   Quevillon S., Robinson J.-C., Berthonneau E., Siatecka M., Mirande M.;
RT   "Macromolecular assemblage of aminoacyl-tRNA synthetases:
RT   identification of protein-protein interactions and characterization of
RT   a core protein.";
RL   J. Mol. Biol. 285:183-195(1999).
RN   [10]
RP   BIDIRECTIONAL PROMOTER WITH TERF2IP.
RX   PubMed=14659874; DOI=10.1016/j.gene.2003.08.026;
RA   Tan M., Wei C., Price C.M.;
RT   "The telomeric protein Rap1 is conserved in vertebrates and is
RT   expressed from a bidirectional promoter positioned between the Rap1
RT   and KARS genes.";
RL   Gene 323:1-10(2003).
RN   [11]
RP   INTERACTION WITH MIFT.
RX   PubMed=14975237; DOI=10.1016/S1074-7613(04)00020-2;
RA   Lee Y.N., Nechushtan H., Figov N., Razin E.;
RT   "The function of lysyl-tRNA synthetase and Ap4A as signaling
RT   regulators of MITF activity in FcepsilonRI-activated mast cells.";
RL   Immunity 20:145-151(2004).
RN   [12]
RP   SUBUNIT, AND INTERACTION WITH HIV-1 GAG.
RX   PubMed=12756246; DOI=10.1074/jbc.M301840200;
RA   Javanbakht H., Halwani R., Cen S., Saadatmand J., Musier-Forsyth K.,
RA   Gottlinger H., Kleiman L.;
RT   "The interaction between HIV-1 Gag and human lysyl-tRNA synthetase
RT   during viral assembly.";
RL   J. Biol. Chem. 278:27644-27651(2003).
RN   [13]
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF 1-MET--GLY-65, AND INTERACTION
RP   WITH AIMP2 AND HIV-1 GAG.
RX   PubMed=15220430; DOI=10.1128/JVI.78.14.7553-7564.2004;
RA   Halwani R., Cen S., Javanbakht H., Saadatmand J., Kim S., Shiba K.,
RA   Kleiman L.;
RT   "Cellular distribution of Lysyl-tRNA synthetase and its interaction
RT   with Gag during human immunodeficiency virus type 1 assembly.";
RL   J. Virol. 78:7553-7564(2004).
RN   [14]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=15851690; DOI=10.1073/pnas.0500226102;
RA   Park S.G., Kim H.J., Min Y.H., Choi E.-C., Shin Y.K., Park B.-J.,
RA   Lee S.W., Kim S.;
RT   "Human lysyl-tRNA synthetase is secreted to trigger proinflammatory
RT   response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:6356-6361(2005).
RN   [15]
RP   INTERACTION WITH EEF1A1; AIMP2 AND DARS.
RX   PubMed=18029264; DOI=10.1016/j.bbrc.2007.11.028;
RA   Guzzo C.M., Yang D.C.H.;
RT   "Lysyl-tRNA synthetase interacts with EF1alpha, aspartyl-tRNA
RT   synthetase and p38 in vitro.";
RL   Biochem. Biophys. Res. Commun. 365:718-723(2008).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-88 AND LYS-141, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.31 ANGSTROMS) OF 70-581 IN COMPLEX WITH
RP   SUBSTRATE AND ATP, AND COFACTOR.
RX   PubMed=18272479; DOI=10.1073/pnas.0712072105;
RA   Guo M., Ignatov M., Musier-Forsyth K., Schimmel P., Yang X.-L.;
RT   "Crystal structure of tetrameric form of human lysyl-tRNA synthetase:
RT   Implications for multisynthetase complex formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2331-2336(2008).
RN   [23]
RP   VARIANTS CMTRIB HIS-105 AND MET-274, AND VARIANT SER-595.
RX   PubMed=20920668; DOI=10.1016/j.ajhg.2010.09.008;
RA   McLaughlin H.M., Sakaguchi R., Liu C., Igarashi T., Pehlivan D.,
RA   Chu K., Iyer R., Cruz P., Cherukuri P.F., Hansen N.F., Mullikin J.C.,
RA   Biesecker L.G., Wilson T.E., Ionasescu V., Nicholson G., Searby C.,
RA   Talbot K., Vance J.M., Zuchner S., Szigeti K., Lupski J.R., Hou Y.M.,
RA   Green E.D., Antonellis A.;
RT   "Compound heterozygosity for loss-of-function lysyl-tRNA synthetase
RT   mutations in a patient with peripheral neuropathy.";
RL   Am. J. Hum. Genet. 87:560-566(2010).
RN   [24]
RP   VARIANTS DFNB89 HIS-145 AND ASN-349.
RX   PubMed=23768514; DOI=10.1016/j.ajhg.2013.05.018;
RG   University of Washington Center for Mendelian Genomics;
RA   Santos-Cortez R.L., Lee K., Azeem Z., Antonellis P.J., Pollock L.M.,
RA   Khan S., Ullah I., Andrade-Elizondo P.B., Chiu I., Adams M.D.,
RA   Basit S., Smith J.D., Nickerson D.A., McDermott B.M. Jr., Ahmad W.,
RA   Leal S.M.;
RT   "Mutations in KARS, encoding lysyl-tRNA synthetase, cause autosomal-
RT   recessive nonsyndromic hearing impairment DFNB89.";
RL   Am. J. Hum. Genet. 93:132-140(2013).
CC   -!- FUNCTION: Catalyzes the specific attachment of an amino acid to
CC       its cognate tRNA in a 2 step reaction: the amino acid (AA) is
CC       first activated by ATP to form AA-AMP and then transferred to the
CC       acceptor end of the tRNA. When secreted, acts as a signaling
CC       molecule that induces immune response through the activation of
CC       monocyte/macrophages. Catalyzes the synthesis of diadenosine
CC       oligophosphate (Ap4A), a signaling molecule involved in the
CC       activation of MITF transcriptional activity. Interacts with HIV-1
CC       virus GAG protein, facilitating the selective packaging of
CC       tRNA(3)(Lys), the primer for reverse transcription initiation.
CC       {ECO:0000269|PubMed:15851690, ECO:0000269|PubMed:5338216}.
CC   -!- CATALYTIC ACTIVITY: ATP + L-lysine + tRNA(Lys) = AMP + diphosphate
CC       + L-lysyl-tRNA(Lys).
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:18272479};
CC   -!- ENZYME REGULATION: Up-regulated by DARS and EEF1A1, but not by
CC       AIMP2.
CC   -!- SUBUNIT: Homodimer; also part of a multisubunit complex that
CC       groups AIMP1, AIMP2, EEF1A1 and tRNA ligases for Arg, Asp, Glu,
CC       Gln, Ile, Leu, Lys, Met and Pro. Interacts with AIMP2 (via N-
CC       terminus) and MITF. Interacts directly with HIV-1 virus GAG
CC       protein. {ECO:0000269|PubMed:12756246,
CC       ECO:0000269|PubMed:14975237, ECO:0000269|PubMed:15220430,
CC       ECO:0000269|PubMed:18029264, ECO:0000269|PubMed:18272479,
CC       ECO:0000269|PubMed:9878398}.
CC   -!- INTERACTION:
CC       Q13155:AIMP2; NbExp=8; IntAct=EBI-356367, EBI-745226;
CC       P08865:RPSA; NbExp=5; IntAct=EBI-356367, EBI-354112;
CC   -!- SUBCELLULAR LOCATION: Isoform Cytoplasmic: Cytoplasm. Nucleus.
CC       Cell membrane; Peripheral membrane protein. Secreted.
CC       Note=Secretion is induced by TNF-alpha.
CC   -!- SUBCELLULAR LOCATION: Isoform Mitochondrial: Mitochondrion.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Cytoplasmic;
CC         IsoId=Q15046-1; Sequence=Displayed;
CC       Name=Mitochondrial;
CC         IsoId=Q15046-2; Sequence=VSP_038481;
CC         Note=Mitochondrial precursor. Contains a mitochondrial transit
CC         peptide at positions 1-16. Ref.2 (AAG30114) sequence is in
CC         conflict in position: 48:R->G. {ECO:0000305};
CC   -!- DOMAIN: The N-terminal domain (1-65) of the cytoplasmic isoform is
CC       a functional tRNA-binding domain (By similarity), is required for
CC       nuclear localization, is involved in the interaction with DARS,
CC       but has a repulsive role in the binding to EEF1A1. A central
CC       domain (208-259) is involved in homodimerization and is required
CC       for interaction with HIV-1 GAG and incorporation into virions. The
CC       C-terminal domain (452-597) is not required for interaction with
CC       AIMP2. {ECO:0000250}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, recessive, intermediate
CC       type, B (CMTRIB) [MIM:613641]: A form of Charcot-Marie-Tooth
CC       disease, a disorder of the peripheral nervous system,
CC       characterized by progressive weakness and atrophy, initially of
CC       the peroneal muscles and later of the distal muscles of the arms.
CC       Recessive intermediate forms of Charcot-Marie-Tooth disease are
CC       characterized by clinical and pathologic features intermediate
CC       between demyelinating and axonal peripheral neuropathies, and
CC       motor median nerve conduction velocities ranging from 25 to 45
CC       m/sec. {ECO:0000269|PubMed:20920668}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Deafness, autosomal recessive, 89 (DFNB89) [MIM:613916]:
CC       A form of non-syndromic deafness characterized by bilateral,
CC       prelingual, moderate to severe hearing loss affecting all
CC       frequencies. {ECO:0000269|PubMed:23768514}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Shares a bidirectional promoter with TERF2IP/RAP1.
CC       {ECO:0000305|PubMed:14659874}.
CC   -!- SIMILARITY: Belongs to the class-II aminoacyl-tRNA synthetase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA06688.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D32053; BAA22084.1; -; mRNA.
DR   EMBL; AF285758; AAG30114.1; -; mRNA.
DR   EMBL; D31890; BAA06688.1; ALT_INIT; mRNA.
DR   EMBL; AC025287; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471114; EAW95622.1; -; Genomic_DNA.
DR   EMBL; CH471114; EAW95624.1; -; Genomic_DNA.
DR   EMBL; BC004132; AAH04132.1; -; mRNA.
DR   CCDS; CCDS10923.1; -. [Q15046-1]
DR   CCDS; CCDS45532.1; -. [Q15046-2]
DR   RefSeq; NP_001123561.1; NM_001130089.1. [Q15046-2]
DR   RefSeq; NP_005539.1; NM_005548.2. [Q15046-1]
DR   UniGene; Hs.3100; -.
DR   PDB; 3BJU; X-ray; 2.31 A; A/B/C/D=70-582.
DR   PDB; 4DPG; X-ray; 2.84 A; A/B/C/D/E/F/G/H=70-581.
DR   PDB; 4YCU; X-ray; 2.10 A; A/B=70-581.
DR   PDB; 4YCW; X-ray; 2.90 A; A/B/E/F=70-581.
DR   PDBsum; 3BJU; -.
DR   PDBsum; 4DPG; -.
DR   PDBsum; 4YCU; -.
DR   PDBsum; 4YCW; -.
DR   ProteinModelPortal; Q15046; -.
DR   SMR; Q15046; -.
DR   BioGrid; 109938; 77.
DR   DIP; DIP-29725N; -.
DR   IntAct; Q15046; 26.
DR   MINT; MINT-1154971; -.
DR   STRING; 9606.ENSP00000325448; -.
DR   BindingDB; Q15046; -.
DR   ChEMBL; CHEMBL5575; -.
DR   DrugBank; DB00123; L-Lysine.
DR   MoonProt; Q15046; -.
DR   iPTMnet; Q15046; -.
DR   PhosphoSitePlus; Q15046; -.
DR   SwissPalm; Q15046; -.
DR   BioMuta; KARS; -.
DR   DMDM; 20178333; -.
DR   EPD; Q15046; -.
DR   MaxQB; Q15046; -.
DR   PaxDb; Q15046; -.
DR   PeptideAtlas; Q15046; -.
DR   PRIDE; Q15046; -.
DR   DNASU; 3735; -.
DR   Ensembl; ENST00000302445; ENSP00000303043; ENSG00000065427. [Q15046-1]
DR   Ensembl; ENST00000319410; ENSP00000325448; ENSG00000065427. [Q15046-2]
DR   GeneID; 3735; -.
DR   KEGG; hsa:3735; -.
DR   UCSC; uc002feq.4; human. [Q15046-1]
DR   CTD; 3735; -.
DR   DisGeNET; 3735; -.
DR   GeneCards; KARS; -.
DR   HGNC; HGNC:6215; KARS.
DR   HPA; HPA041345; -.
DR   HPA; HPA041550; -.
DR   MalaCards; KARS; -.
DR   MIM; 601421; gene.
DR   MIM; 613641; phenotype.
DR   MIM; 613916; phenotype.
DR   neXtProt; NX_Q15046; -.
DR   OpenTargets; ENSG00000065427; -.
DR   Orphanet; 254334; Autosomal recessive intermediate Charcot-Marie-Tooth disease type B.
DR   Orphanet; 90636; Autosomal recessive non-syndromic sensorineural deafness type DFNB.
DR   PharmGKB; PA30016; -.
DR   eggNOG; KOG1885; Eukaryota.
DR   eggNOG; COG1190; LUCA.
DR   GeneTree; ENSGT00550000074841; -.
DR   HOGENOM; HOG000236577; -.
DR   HOVERGEN; HBG002562; -.
DR   InParanoid; Q15046; -.
DR   KO; K04567; -.
DR   OMA; HHNTLDI; -.
DR   OrthoDB; EOG091G03SI; -.
DR   PhylomeDB; Q15046; -.
DR   TreeFam; TF300365; -.
DR   BRENDA; 6.1.1.6; 2681.
DR   Reactome; R-HSA-2408517; SeMet incorporation into proteins.
DR   Reactome; R-HSA-379716; Cytosolic tRNA aminoacylation.
DR   Reactome; R-HSA-379726; Mitochondrial tRNA aminoacylation.
DR   SIGNOR; Q15046; -.
DR   ChiTaRS; KARS; human.
DR   EvolutionaryTrace; Q15046; -.
DR   GeneWiki; KARS_(gene); -.
DR   GenomeRNAi; 3735; -.
DR   PRO; PR:Q15046; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000065427; -.
DR   CleanEx; HS_KARS; -.
DR   ExpressionAtlas; Q15046; baseline and differential.
DR   Genevisible; Q15046; HS.
DR   GO; GO:0017101; C:aminoacyl-tRNA synthetase multienzyme complex; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005615; C:extracellular space; IDA:CAFA.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016597; F:amino acid binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004824; F:lysine-tRNA ligase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000049; F:tRNA binding; NAS:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:CAFA.
DR   GO; GO:0002276; P:basophil activation involved in immune response; IGI:CAFA.
DR   GO; GO:0015966; P:diadenosine tetraphosphate biosynthetic process; IGI:CAFA.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IGI:CAFA.
DR   GO; GO:0006430; P:lysyl-tRNA aminoacylation; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:CAFA.
DR   GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IDA:CAFA.
DR   GO; GO:0002741; P:positive regulation of cytokine secretion involved in immune response; IDA:CAFA.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:CAFA.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; IDA:CAFA.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IDA:CAFA.
DR   GO; GO:1905050; P:positive regulation of metallopeptidase activity; IDA:CAFA.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; IDA:CAFA.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IGI:CAFA.
DR   GO; GO:0006418; P:tRNA aminoacylation for protein translation; TAS:Reactome.
DR   GO; GO:0008033; P:tRNA processing; NAS:UniProtKB.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IDA:CAFA.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd00775; LysRS_core; 1.
DR   HAMAP; MF_00252; Lys_tRNA_synth_class2; 1.
DR   InterPro; IPR004364; aa-tRNA-synt_II.
DR   InterPro; IPR006195; aa-tRNA-synth_II.
DR   InterPro; IPR002313; Lys-tRNA-ligase_II.
DR   InterPro; IPR034762; Lys-tRNA-ligase_II_bac/euk.
DR   InterPro; IPR018149; Lys-tRNA-synth_II_C.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR004365; NA-bd_OB_tRNA.
DR   Pfam; PF00152; tRNA-synt_2; 1.
DR   Pfam; PF01336; tRNA_anti-codon; 1.
DR   PIRSF; PIRSF039101; LysRS2; 1.
DR   PRINTS; PR00982; TRNASYNTHLYS.
DR   SUPFAM; SSF50249; SSF50249; 1.
DR   TIGRFAMs; TIGR00499; lysS_bact; 1.
DR   PROSITE; PS50862; AA_TRNA_LIGASE_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Aminoacyl-tRNA synthetase; ATP-binding; Cell membrane;
KW   Charcot-Marie-Tooth disease; Complete proteome; Cytoplasm; Deafness;
KW   Direct protein sequencing; Disease mutation; Host-virus interaction;
KW   Ligase; Membrane; Metal-binding; Mitochondrion; Neurodegeneration;
KW   Neuropathy; Non-syndromic deafness; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Protein biosynthesis;
KW   Reference proteome; Secreted.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.7}.
FT   CHAIN         2    597       Lysine--tRNA ligase.
FT                                /FTId=PRO_0000152765.
FT   NP_BIND     323    325       ATP. {ECO:0000269|PubMed:18272479}.
FT   NP_BIND     331    332       ATP. {ECO:0000269|PubMed:18272479}.
FT   NP_BIND     494    495       ATP. {ECO:0000269|PubMed:18272479}.
FT   NP_BIND     550    553       ATP. {ECO:0000269|PubMed:18272479}.
FT   METAL       487    487       Calcium. {ECO:0000269|PubMed:18272479}.
FT   METAL       494    494       Calcium. {ECO:0000269|PubMed:18272479}.
FT   BINDING     277    277       Substrate; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:18272479}.
FT   BINDING     301    301       Substrate. {ECO:0000269|PubMed:18272479}.
FT   BINDING     339    339       Substrate. {ECO:0000269|PubMed:18272479}.
FT   BINDING     341    341       Substrate. {ECO:0000269|PubMed:18272479}.
FT   BINDING     497    497       Substrate. {ECO:0000269|PubMed:18272479}.
FT   BINDING     501    501       Substrate. {ECO:0000269|PubMed:18272479}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.7}.
FT   MOD_RES      88     88       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     141    141       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     590    590       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99MN1}.
FT   MOD_RES     591    591       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q99MN1}.
FT   MOD_RES     596    596       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99MN1}.
FT   VAR_SEQ       1     21       MAAVQAAEVKVDGSEPKLSKN -> MLTQAAVRLVRGSLRK
FT                                TSWAEWGHRELRLGQLAPFTAPHKDKSFSDQRS (in
FT                                isoform Mitochondrial).
FT                                {ECO:0000303|PubMed:10952987}.
FT                                /FTId=VSP_038481.
FT   VARIANT     105    105       L -> H (in CMTRIB; severely affects
FT                                enzyme activity; dbSNP:rs267607194).
FT                                {ECO:0000269|PubMed:20920668}.
FT                                /FTId=VAR_064911.
FT   VARIANT     145    145       Y -> H (in DFNB89; dbSNP:rs397514745).
FT                                {ECO:0000269|PubMed:23768514}.
FT                                /FTId=VAR_070233.
FT   VARIANT     179    179       G -> A (in dbSNP:rs11557665).
FT                                /FTId=VAR_052640.
FT   VARIANT     274    274       I -> M (in CMTRIB; dbSNP:rs146955132).
FT                                {ECO:0000269|PubMed:20920668}.
FT                                /FTId=VAR_064912.
FT   VARIANT     349    349       D -> N (in DFNB89; dbSNP:rs397514746).
FT                                {ECO:0000269|PubMed:23768514}.
FT                                /FTId=VAR_070234.
FT   VARIANT     595    595       T -> S (in dbSNP:rs6834).
FT                                {ECO:0000269|PubMed:10952987,
FT                                ECO:0000269|PubMed:20920668,
FT                                ECO:0000269|PubMed:7584044}.
FT                                /FTId=VAR_016105.
FT   MUTAGEN       1     65       Missing: Loss of nuclear localization,
FT                                but no effect on packaging into HIV-1.
FT                                {ECO:0000269|PubMed:15220430}.
FT   HELIX        73     89       {ECO:0000244|PDB:4YCU}.
FT   HELIX       105    112       {ECO:0000244|PDB:4YCU}.
FT   STRAND      126    137       {ECO:0000244|PDB:4YCU}.
FT   STRAND      139    149       {ECO:0000244|PDB:4YCU}.
FT   STRAND      152    159       {ECO:0000244|PDB:4YCU}.
FT   HELIX       160    162       {ECO:0000244|PDB:4YCU}.
FT   HELIX       166    175       {ECO:0000244|PDB:4YCU}.
FT   STRAND      181    190       {ECO:0000244|PDB:4YCU}.
FT   STRAND      196    207       {ECO:0000244|PDB:4YCU}.
FT   TURN        216    218       {ECO:0000244|PDB:4YCU}.
FT   HELIX       223    228       {ECO:0000244|PDB:4YCU}.
FT   HELIX       230    236       {ECO:0000244|PDB:4YCU}.
FT   HELIX       238    260       {ECO:0000244|PDB:4YCU}.
FT   STRAND      270    274       {ECO:0000244|PDB:4YCU}.
FT   STRAND      277    279       {ECO:0000244|PDB:3BJU}.
FT   STRAND      284    287       {ECO:0000244|PDB:4YCU}.
FT   TURN        288    291       {ECO:0000244|PDB:4YCU}.
FT   STRAND      292    296       {ECO:0000244|PDB:4YCU}.
FT   HELIX       301    309       {ECO:0000244|PDB:4YCU}.
FT   STRAND      314    322       {ECO:0000244|PDB:4YCU}.
FT   STRAND      328    330       {ECO:0000244|PDB:4DPG}.
FT   STRAND      333    343       {ECO:0000244|PDB:4YCU}.
FT   HELIX       347    366       {ECO:0000244|PDB:4YCU}.
FT   STRAND      367    373       {ECO:0000244|PDB:4YCU}.
FT   STRAND      383    386       {ECO:0000244|PDB:4YCU}.
FT   STRAND      392    395       {ECO:0000244|PDB:4YCU}.
FT   HELIX       396    404       {ECO:0000244|PDB:4YCU}.
FT   HELIX       411    413       {ECO:0000244|PDB:3BJU}.
FT   HELIX       417    429       {ECO:0000244|PDB:4YCU}.
FT   HELIX       440    451       {ECO:0000244|PDB:4YCU}.
FT   HELIX       453    455       {ECO:0000244|PDB:4YCU}.
FT   STRAND      460    463       {ECO:0000244|PDB:4YCU}.
FT   HELIX       467    469       {ECO:0000244|PDB:4YCU}.
FT   STRAND      477    479       {ECO:0000244|PDB:4YCU}.
FT   STRAND      482    490       {ECO:0000244|PDB:4YCU}.
FT   STRAND      493    501       {ECO:0000244|PDB:4YCU}.
FT   HELIX       505    519       {ECO:0000244|PDB:4YCU}.
FT   TURN        520    522       {ECO:0000244|PDB:4YCU}.
FT   STRAND      524    526       {ECO:0000244|PDB:4YCW}.
FT   HELIX       531    538       {ECO:0000244|PDB:4YCU}.
FT   STRAND      543    550       {ECO:0000244|PDB:4YCU}.
FT   HELIX       551    558       {ECO:0000244|PDB:4YCU}.
FT   HELIX       564    567       {ECO:0000244|PDB:4YCU}.
FT   STRAND      568    570       {ECO:0000244|PDB:4DPG}.
SQ   SEQUENCE   597 AA;  68048 MW;  E7770953332D905D CRC64;
     MAAVQAAEVK VDGSEPKLSK NELKRRLKAE KKVAEKEAKQ KELSEKQLSQ ATAAATNHTT
     DNGVGPEEES VDPNQYYKIR SQAIHQLKVN GEDPYPHKFH VDISLTDFIQ KYSHLQPGDH
     LTDITLKVAG RIHAKRASGG KLIFYDLRGE GVKLQVMANS RNYKSEEEFI HINNKLRRGD
     IIGVQGNPGK TKKGELSIIP YEITLLSPCL HMLPHLHFGL KDKETRYRQR YLDLILNDFV
     RQKFIIRSKI ITYIRSFLDE LGFLEIETPM MNIIPGGAVA KPFITYHNEL DMNLYMRIAP
     ELYHKMLVVG GIDRVYEIGR QFRNEGIDLT HNPEFTTCEF YMAYADYHDL MEITEKMVSG
     MVKHITGSYK VTYHPDGPEG QAYDVDFTPP FRRINMVEEL EKALGMKLPE TNLFETEETR
     KILDDICVAK AVECPPPRTT ARLLDKLVGE FLEVTCINPT FICDHPQIMS PLAKWHRSKE
     GLTERFELFV MKKEICNAYT ELNDPMRQRQ LFEEQAKAKA AGDDEAMFID ENFCTALEYG
     LPPTAGWGMG IDRVAMFLTD SNNIKEVLLF PAMKPEDKKE NVATTDTLES TTVGTSV
//
